

Dated: July 21, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026-14966 Filed 7-23-26; 8:45 am]

BILLING CODE 41467-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The NCI seeks research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of AML.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this license opportunity should be directed to: Abritee Dhal, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: abritee.dhal@nih.gov or Phone: 240-276-6154.

SUPPLEMENTARY INFORMATION: AML is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis and a 5-year survival rate of ~33%. Current treatments, including intensive chemotherapy and stem cell transplantation, are not suitable for all patients and can cause significant toxicities, including low blood cell counts, infection and graft-versus-host disease. Therefore, there is a need for safer and more effective treatments.

This specific invention concerns the isolation of two highly specific T cell receptors (TCRs), known as TCR6 and TCR7, recognizing a neoepitope, AVEEVSLRK. The neoepitope is derived from mutant NPM1 and presented in the context of HLA-A*11:01. Pre-clinical results for these TCRs revealed robust and specific cytotoxicity against a leukemia cell line and several patient-derived AML samples expressing the NPM1 mutation and HLA-A*11:01. Furthermore, they showed no cross-reactivity to normal peripheral blood mononuclear cells, structurally similar peptides or unrelated HLA alleles. These results suggest these novel TCRs represent a potential adoptive T cell therapy for the treatment of AML.

“This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.”
NIH Reference Number: E-200-2025-

0.
Related Technologies: N/A.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology.
Development Stage: Pre-clinical (in vivo validation).

Publications:

- Aidan Pursley, et al., T cell receptors targeting mutant NPM1 for adoptive cell therapy in acute myeloid leukemia, (<https://doi.org/10.1182/blood-2025-4132>).

Patents: U.S. Provisional Patent Application, 63/908,266, filed October, 30-2025.

Potential Commercial Applications:

- Acute myeloid leukemia patients expressing HLA-A*11:01.

Competitive Advantages:

- Highly specific targeting of mutant NPM1.

- Minimal off-target effects with enhanced safety profile.

- Significant unmet medical need for AML patients.

Collaboration Opportunity:

Researchers at the NCI seek licensing and/or co-development research collaborations for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.

Dated: July 21, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026-14981 Filed 7-23-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review, Special Emphasis Panel; Career Development Applications in Neuroscience.

Date: August 19, 2026.

Time: 10:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Dorela Doris Shuboni-Mulligan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-1823, dorela.shuboni-mulligan@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 21, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-14964 Filed 7-23-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

[OMB Control Number 1615-0116]

Agency Information Collection Activities; Extension, Without Change, of a Currently Approved Collection: Request for Fee Waiver

AGENCY: U.S. Citizenship and Immigration Services, Department of Homeland Security.

ACTION: 30-Day notice.

SUMMARY: The Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The purpose of this notice is to allow an additional 30 days for public comments.

DATES: Comments are encouraged and will be accepted until August 24, 2026.

ADDRESSES: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, must be submitted via the Federal eRulemaking Portal website at <http://www.regulations.gov>

under e-Docket ID number USCIS-2010-0008. All submissions received must include the OMB Control Number 1615-0116 in the